世界の加齢性黄斑変性症向け遺伝子治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Gene Therapy for Age-related Macular Degeneration Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z2517 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、加齢性黄斑変性症向け遺伝子治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（網膜下、硝子体内）、用途別市場規模（単剤療法、併用療法）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・加齢性黄斑変性症向け遺伝子治療の市場動向 ・企業の競争状況、市場シェア ・加齢性黄斑変性症向け遺伝子治療の種類別市場規模（網膜下、硝子体内） ・加齢性黄斑変性症向け遺伝子治療の用途別市場規模（単剤療法、併用療法） ・加齢性黄斑変性症向け遺伝子治療の北米市場規模2016-2027（アメリカ、カナダ） ・加齢性黄斑変性症向け遺伝子治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・加齢性黄斑変性症向け遺伝子治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・加齢性黄斑変性症向け遺伝子治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・加齢性黄斑変性症向け遺伝子治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（RetroSense Therapeutics、REGENXBIO、AGTC） ・結論

Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is directly related to the advancement of age. But smoking also plays a vital role in causing AMD. AMD is characterized by the presence of a blurred area near the center of vision that leads to distorted vision. There are two different types of AMD, including dry (atrophic) AMD (dAMD) and wet (neovascular/exudative) AMD (wAMD). The dAMD is the most common type of AMD and accounts for almost 80%-90% of the overall AMD cases.
It has been observed that age-related macular degeneration (AMD) is one of the major causes for vision loss and is characterized by the formation of a blurred area near the center of vision, a condition that mostly affects the geriatric population. According to the CDC, almost 2 million individuals in the US suffer from AMD and by 2050, this number will reach more than 5 million. This will subsequently demand the need for the development of innovative treatments for AMD, driving the market’s growth.

Market Analysis and Insights: Global Gene Therapy for Age-related Macular Degeneration Market
The global Gene Therapy for Age-related Macular Degeneration market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Gene Therapy for Age-related Macular Degeneration market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Gene Therapy for Age-related Macular Degeneration market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Gene Therapy for Age-related Macular Degeneration market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Gene Therapy for Age-related Macular Degeneration market.

Global Gene Therapy for Age-related Macular Degeneration Scope and Market Size
Gene Therapy for Age-related Macular Degeneration market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Gene Therapy for Age-related Macular Degeneration market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Subretinal
Intravitreal

Segment by Application
Monotherapy
Combination Therapy

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
RetroSense Therapeutics

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Subretinal
1.2.3 Intravitreal
1.3 Market by Application
1.3.1 Global Gene Therapy for Age-related Macular Degeneration Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Monotherapy
1.3.3 Combination Therapy
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Gene Therapy for Age-related Macular Degeneration Market Perspective (2016-2027)
2.2 Gene Therapy for Age-related Macular Degeneration Growth Trends by Regions
2.2.1 Gene Therapy for Age-related Macular Degeneration Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Gene Therapy for Age-related Macular Degeneration Historic Market Share by Regions (2016-2021)
2.2.3 Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Regions (2022-2027)
2.3 Gene Therapy for Age-related Macular Degeneration Industry Dynamic
2.3.1 Gene Therapy for Age-related Macular Degeneration Market Trends
2.3.2 Gene Therapy for Age-related Macular Degeneration Market Drivers
2.3.3 Gene Therapy for Age-related Macular Degeneration Market Challenges
2.3.4 Gene Therapy for Age-related Macular Degeneration Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Gene Therapy for Age-related Macular Degeneration Players by Revenue
3.1.1 Global Top Gene Therapy for Age-related Macular Degeneration Players by Revenue (2016-2021)
3.1.2 Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Players (2016-2021)
3.2 Global Gene Therapy for Age-related Macular Degeneration Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Gene Therapy for Age-related Macular Degeneration Revenue
3.4 Global Gene Therapy for Age-related Macular Degeneration Market Concentration Ratio
3.4.1 Global Gene Therapy for Age-related Macular Degeneration Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gene Therapy for Age-related Macular Degeneration Revenue in 2020
3.5 Gene Therapy for Age-related Macular Degeneration Key Players Head office and Area Served
3.6 Key Players Gene Therapy for Age-related Macular Degeneration Product Solution and Service
3.7 Date of Enter into Gene Therapy for Age-related Macular Degeneration Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Gene Therapy for Age-related Macular Degeneration Breakdown Data by Type
4.1 Global Gene Therapy for Age-related Macular Degeneration Historic Market Size by Type (2016-2021)
4.2 Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Type (2022-2027)

5 Gene Therapy for Age-related Macular Degeneration Breakdown Data by Application
5.1 Global Gene Therapy for Age-related Macular Degeneration Historic Market Size by Application (2016-2021)
5.2 Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Gene Therapy for Age-related Macular Degeneration Market Size (2016-2027)
6.2 North America Gene Therapy for Age-related Macular Degeneration Market Size by Type
6.2.1 North America Gene Therapy for Age-related Macular Degeneration Market Size by Type (2016-2021)
6.2.2 North America Gene Therapy for Age-related Macular Degeneration Market Size by Type (2022-2027)
6.2.3 North America Gene Therapy for Age-related Macular Degeneration Market Size by Type (2016-2027)
6.3 North America Gene Therapy for Age-related Macular Degeneration Market Size by Application
6.3.1 North America Gene Therapy for Age-related Macular Degeneration Market Size by Application (2016-2021)
6.3.2 North America Gene Therapy for Age-related Macular Degeneration Market Size by Application (2022-2027)
6.3.3 North America Gene Therapy for Age-related Macular Degeneration Market Size by Application (2016-2027)
6.4 North America Gene Therapy for Age-related Macular Degeneration Market Size by Country
6.4.1 North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2016-2021)
6.4.2 North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Gene Therapy for Age-related Macular Degeneration Market Size (2016-2027)
7.2 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Type
7.2.1 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Type (2016-2021)
7.2.2 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Type (2022-2027)
7.2.3 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Type (2016-2027)
7.3 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Application
7.3.1 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Application (2016-2021)
7.3.2 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Application (2022-2027)
7.3.3 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Application (2016-2027)
7.4 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country
7.4.1 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2016-2021)
7.4.2 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size (2016-2027)
8.2 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Type
8.2.1 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Type (2016-2027)
8.3 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Application
8.3.1 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Application (2016-2027)
8.4 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region
8.4.1 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Gene Therapy for Age-related Macular Degeneration Market Size (2016-2027)
9.2 Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Type
9.2.1 Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Type (2016-2021)
9.2.2 Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Type (2022-2027)
9.2.3 Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Type (2016-2027)
9.3 Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Application
9.3.1 Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Application (2016-2021)
9.3.2 Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Application (2022-2027)
9.3.3 Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Application (2016-2027)
9.4 Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country
9.4.1 Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2016-2021)
9.4.2 Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size (2016-2027)
10.2 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Type
10.2.1 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Type (2016-2027)
10.3 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Application
10.3.1 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Application (2016-2027)
10.4 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country
10.4.1 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 RetroSense Therapeutics
11.1.1 RetroSense Therapeutics Company Details
11.1.2 RetroSense Therapeutics Business Overview
11.1.3 RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Introduction
11.1.4 RetroSense Therapeutics Revenue in Gene Therapy for Age-related Macular Degeneration Business (2016-2021)
11.1.5 RetroSense Therapeutics Recent Development
11.2 REGENXBIO
11.2.1 REGENXBIO Company Details
11.2.2 REGENXBIO Business Overview
11.2.3 REGENXBIO Gene Therapy for Age-related Macular Degeneration Introduction
11.2.4 REGENXBIO Revenue in Gene Therapy for Age-related Macular Degeneration Business (2016-2021)
11.2.5 REGENXBIO Recent Development
11.3 AGTC
11.3.1 AGTC Company Details
11.3.2 AGTC Business Overview
11.3.3 AGTC Gene Therapy for Age-related Macular Degeneration Introduction
11.3.4 AGTC Revenue in Gene Therapy for Age-related Macular Degeneration Business (2016-2021)
11.3.5 AGTC Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Subretinal
Table 3. Key Players of Intravitreal
Table 4. Global Gene Therapy for Age-related Macular Degeneration Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Gene Therapy for Age-related Macular Degeneration Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Gene Therapy for Age-related Macular Degeneration Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Gene Therapy for Age-related Macular Degeneration Market Share by Regions (2016-2021)
Table 8. Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Gene Therapy for Age-related Macular Degeneration Market Share by Regions (2022-2027)
Table 10. Gene Therapy for Age-related Macular Degeneration Market Trends
Table 11. Gene Therapy for Age-related Macular Degeneration Market Drivers
Table 12. Gene Therapy for Age-related Macular Degeneration Market Challenges
Table 13. Gene Therapy for Age-related Macular Degeneration Market Restraints
Table 14. Global Gene Therapy for Age-related Macular Degeneration Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Gene Therapy for Age-related Macular Degeneration Market Share by Players (2016-2021)
Table 16. Global Top Gene Therapy for Age-related Macular Degeneration Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gene Therapy for Age-related Macular Degeneration as of 2020)
Table 17. Ranking of Global Top Gene Therapy for Age-related Macular Degeneration Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Gene Therapy for Age-related Macular Degeneration Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Gene Therapy for Age-related Macular Degeneration Product Solution and Service
Table 21. Date of Enter into Gene Therapy for Age-related Macular Degeneration Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Gene Therapy for Age-related Macular Degeneration Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Type (2016-2021)
Table 25. Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Gene Therapy for Age-related Macular Degeneration Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Application (2016-2021)
Table 29. Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Gene Therapy for Age-related Macular Degeneration Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Gene Therapy for Age-related Macular Degeneration Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Gene Therapy for Age-related Macular Degeneration Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Gene Therapy for Age-related Macular Degeneration Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Gene Therapy for Age-related Macular Degeneration Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Gene Therapy for Age-related Macular Degeneration Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Gene Therapy for Age-related Macular Degeneration Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Gene Therapy for Age-related Macular Degeneration Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2022-2027) & (US$ Million)
Table 61. RetroSense Therapeutics Company Details
Table 62. RetroSense Therapeutics Business Overview
Table 63. RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Product
Table 64. RetroSense Therapeutics Revenue in Gene Therapy for Age-related Macular Degeneration Business (2016-2021) & (US$ Million)
Table 65. RetroSense Therapeutics Recent Development
Table 66. REGENXBIO Company Details
Table 67. REGENXBIO Business Overview
Table 68. REGENXBIO Gene Therapy for Age-related Macular Degeneration Product
Table 69. REGENXBIO Revenue in Gene Therapy for Age-related Macular Degeneration Business (2016-2021) & (US$ Million)
Table 70. REGENXBIO Recent Development
Table 71. AGTC Company Details
Table 72. AGTC Business Overview
Table 73. AGTC Gene Therapy for Age-related Macular Degeneration Product
Table 74. AGTC Revenue in Gene Therapy for Age-related Macular Degeneration Business (2016-2021) & (US$ Million)
Table 75. AGTC Recent Development
Table 76. Research Programs/Design for This Report
Table 77. Key Data Information from Secondary Sources
Table 78. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Gene Therapy for Age-related Macular Degeneration Market Share by Type: 2020 VS 2027
Figure 2. Subretinal Features
Figure 3. Intravitreal Features
Figure 4. Global Gene Therapy for Age-related Macular Degeneration Market Share by Application: 2020 VS 2027
Figure 5. Monotherapy Case Studies
Figure 6. Combination Therapy Case Studies
Figure 7. Gene Therapy for Age-related Macular Degeneration Report Years Considered
Figure 8. Global Gene Therapy for Age-related Macular Degeneration Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 9. Global Gene Therapy for Age-related Macular Degeneration Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 10. Global Gene Therapy for Age-related Macular Degeneration Market Share by Regions: 2020 VS 2027
Figure 11. Global Gene Therapy for Age-related Macular Degeneration Market Share by Regions (2022-2027)
Figure 12. Global Gene Therapy for Age-related Macular Degeneration Market Share by Players in 2020
Figure 13. Global Top Gene Therapy for Age-related Macular Degeneration Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gene Therapy for Age-related Macular Degeneration as of 2020
Figure 14. The Top 10 and 5 Players Market Share by Gene Therapy for Age-related Macular Degeneration Revenue in 2020
Figure 15. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Type (2016-2021)
Figure 16. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Type (2022-2027)
Figure 17. North America Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 18. North America Gene Therapy for Age-related Macular Degeneration Market Share by Type (2016-2027)
Figure 19. North America Gene Therapy for Age-related Macular Degeneration Market Share by Application (2016-2027)
Figure 20. North America Gene Therapy for Age-related Macular Degeneration Market Share by Country (2016-2027)
Figure 21. United States Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. Canada Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Europe Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Gene Therapy for Age-related Macular Degeneration Market Share by Type (2016-2027)
Figure 25. Europe Gene Therapy for Age-related Macular Degeneration Market Share by Application (2016-2027)
Figure 26. Europe Gene Therapy for Age-related Macular Degeneration Market Share by Country (2016-2027)
Figure 27. Germany Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. France Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. U.K. Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Italy Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Russia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Nordic Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Share by Type (2016-2027)
Figure 35. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Share by Application (2016-2027)
Figure 36. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Share by Region (2016-2027)
Figure 37. China Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Japan Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. South Korea Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. India Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Australia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Latin America Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Gene Therapy for Age-related Macular Degeneration Market Share by Type (2016-2027)
Figure 45. Latin America Gene Therapy for Age-related Macular Degeneration Market Share by Application (2016-2027)
Figure 46. Latin America Gene Therapy for Age-related Macular Degeneration Market Share by Country (2016-2027)
Figure 47. Mexico Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Brazil Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Share by Type (2016-2027)
Figure 51. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Share by Application (2016-2027)
Figure 52. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Share by Country (2016-2027)
Figure 53. Turkey Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Saudi Arabia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. UAE Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. RetroSense Therapeutics Revenue Growth Rate in Gene Therapy for Age-related Macular Degeneration Business (2016-2021)
Figure 57. REGENXBIO Revenue Growth Rate in Gene Therapy for Age-related Macular Degeneration Business (2016-2021)
Figure 58. AGTC Revenue Growth Rate in Gene Therapy for Age-related Macular Degeneration Business (2016-2021)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed

---